Vincent Keunen, founder and CEO of Andaman7 shares his thoughts on how industry can achieve true patient centricity through emerging platforms and digital tools.
Related Posts
The Impact of ICH E6(R3) on Biospecimen Management
With the EMA adopting ICH E6(R3) in July, sponsors with EU trial operations must now meet stricter regulations that directly…
Phase III INDIGO Trial Data Lead to FDA Priority Review for Vorasidenib in IDH-Mutant Gliomas
Image credit: freshidea | stock.adobe.com. The FDA has granted Priority Review status to a New Drug Application (NDA) for vorasidenib,…
Creating a Global Standard for Data Sources
In a recent video interview with Applied Clinical Trials, Mark Melton, vice president of biospecimen data and operations, Slope, discussed…